AbbVie signs patent license agreements with Pfizer over Humira biosimilar

AbbVie (ABBV) announced patent license agreements with Pfizer (PFE) over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie’s intellectual property relating to Humira in the United States and in various other countries around the world in which AbbVie has intellectual property. Pfizer’s U.S. license will begin on November 20, 2023, and will not be accelerated by the entry of companies who have already taken a license. And in the European Union, Pfizer can launch upon approval from the European Medicines Agency. Pfizer will pay royalties to AbbVie for licensing its Humira patents and “acknowledges the validity of the licensed patents,’ AbbVie says in a statement. The company will make no payments to Pfizer. The precise terms are confidential between the parties, it added.
https://thefly.com/landingPageNews.php?id=2830551